YMTracker DRIPCalc v2 Launch sale

NEW Dividend Portfolio Tracker (DRIPTracker) is Now Live!

Add your stocks and see every dividend they pay you — dates, amounts, and reinvested shares.

AGIO | NASDAQ

$33.30 -$0.12 | -0.36%

SIGNAL:

Signal available — unlock to view

|2026-09-25 |F&G 38 |RSI 48.8

Add to favoritesFavorite

Company Overview:

Market Cap: $1.99B

Trailing PE: N/A

FWD PE: —

Payout Ratio (TTM): —

52-Week Range: $22.24 - $46.00

10 Year AGIO Performance Metrics:

Total Return (with DRIP): -37.0% (-4.51% CAGR)

Total Return (no DRIP): -37.0% (-4.51% CAGR)

Share Price: -37.0% (-4.51% CAGR)

Yield on Cost (with DRIP): —

Total Invested: $10,000

Total Value (with DRIP): $6,304

Total Return $ (with DRIP): -$3,696

AGIO Total Return

1M 3M 6M YTD 1Y 3Y 5Y 10Y

AGIO Price Chart

1M 3M 6M YTD 1Y 3Y 5Y 10Y All

Unlock All Reports & Research Dividend Stocks like a BOSS!

Save 25% with annual plan (3 Months Free)

Pro

$171 ($14.25/mo) $102.60/yr ($8.55/mo)

7-day free trial

Unlimited Portfolio Tracker
Portfolio - Lots/Sales/Dividends
Portfolio Auto-DRIP
Stock Fundamentals
DCF valuation modeling
Compare Stocks Side-by-Side
Revenue & EPS Estimates

Try it free for 7 days

You save $125.40 (55%)

Most Popular

Premium

$288 ($24/mo) $172.80/yr ($14.40/mo)

7-day free trial

Everything in Pro
YieldMax PNL Tracker
YieldMax NAV Erosion Alerts
Stocks Dashboard

Try it free for 7 days

You save $211.20 (55%)

Ultra

$576 ($48/mo) $345.60/yr ($28.80/mo)

7-day free trial

Everything in Premium
Group & weekly ETF estimates
YouTuber Mode
Trades summary + CSV export
Priority data & support

Try it free for 7 days

You save $422.40 (55%)

AGIO Fundamentals: Earnings, Revenue, Cash Flow, Ebitda, Cash/Debt, Shares Float, etc:

AGIO - Revenue

AGIO Revenue CAGR:1Y: 0.00%2Y: 0.00%5Y: 0.00%10Y: 0.00%

AGIO - Earnings Per Share (EPS)

AGIO EPS CAGR:1Y: 0.00%2Y: 0.00%5Y: 0.00%10Y: 0.00%

AGIO - Net Income

🔓 See the full chart40% off right now · 7-day free trial

AGIO Net Income CAGR:1Y: 0.00%2Y: 0.00%5Y: 0.00%10Y: 0.00%

AGIO - EBITDA

🔓 See the full chart40% off right now · 7-day free trial

AGIO EBITDA CAGR:1Y: 0.00%2Y: 0.00%5Y: 0.00%10Y: 0.00%

AGIO - Free Cash Flow

🔓 See the full chart40% off right now · 7-day free trial

AGIO Free Cash Flow CAGR:1Y: 0.00%2Y: 0.00%5Y: 0.00%10Y: 0.00%

AGIO - Free Cash Flow / Share

🔓 See the full chart40% off right now · 7-day free trial

AGIO Free Cash Flow / Share CAGR:1Y: 0.00%2Y: 0.00%5Y: 0.00%10Y: 0.00%

AGIO - Operating Income

🔓 See the full chart40% off right now · 7-day free trial

AGIO Operating Income CAGR:1Y: 0.00%2Y: 0.00%5Y: 0.00%10Y: 0.00%

AGIO - Gross Profit

🔓 See the full chart40% off right now · 7-day free trial

AGIO Gross Profit CAGR:1Y: 0.00%2Y: 0.00%5Y: 0.00%10Y: 0.00%

AGIO - Shares Outstanding

🔓 See the full chart40% off right now · 7-day free trial

AGIO Shares Outstanding CAGR:1Y: 0.00%2Y: 0.00%5Y: 0.00%10Y: 0.00%

AGIO - Share Buybacks

🔓 See the full chart40% off right now · 7-day free trial

AGIO Share Buybacks CAGR:1Y: 0.00%2Y: 0.00%5Y: 0.00%10Y: 0.00%

AGIO - Stock-Based Comp

🔓 See the full chart40% off right now · 7-day free trial

AGIO Stock-Based Comp CAGR:1Y: 0.00%2Y: 0.00%5Y: 0.00%10Y: 0.00%

AGIO - Expenses

🔓 See the full chart40% off right now · 7-day free trial

AGIO Expenses CAGR:1Y: 0.00%2Y: 0.00%5Y: 0.00%10Y: 0.00%

AGIO - Revenue vs Net Income

🔓 See the full chart40% off right now · 7-day free trial

AGIO - EPS vs FCF / Share

🔓 See the full chart40% off right now · 7-day free trial

AGIO - EPS vs PE Ratio

🔓 See the full chart40% off right now · 7-day free trial

AGIO - FCF vs FCF / Share

🔓 See the full chart40% off right now · 7-day free trial

AGIO - FCF vs Stock Based Comp

🔓 See the full chart40% off right now · 7-day free trial

AGIO - Cash & Debt

🔓 See the full chart40% off right now · 7-day free trial

AGIO - Revenue by Segment

🔓 See the full chart40% off right now · 7-day free trial

AGIO Revenue CAGR:1Y: 0.00%2Y: 0.00%5Y: 0.00%10Y: 0.00%

AGIO - Revenue by Region

🔓 See the full chart40% off right now · 7-day free trial

AGIO Revenue CAGR:1Y: 0.00%2Y: 0.00%5Y: 0.00%10Y: 0.00%

Revenue, EPS, Net Income & Ebitda - Estimates VS Actual:

AGIO - REVENUE: Actual + Estimates

🔓 See the full chart40% off right now · 7-day free trial

AGIO Actual Revenue CAGR:1Y: 0.00%2Y: 0.00%5Y: 0.00%10Y: 0.00%

AGIO - EPS: Actual + Estimates

🔓 See the full chart40% off right now · 7-day free trial

AGIO Actual EPS CAGR:1Y: 0.00%2Y: 0.00%5Y: 0.00%10Y: 0.00%

AGIO - NET INCOME: Actual + Estimates

🔓 See the full chart40% off right now · 7-day free trial

AGIO Actual Net Income CAGR:1Y: 0.00%2Y: 0.00%5Y: 0.00%10Y: 0.00%

AGIO - EBITDA: Actual + Estimates

🔓 See the full chart40% off right now · 7-day free trial

AGIO Actual EBITDA CAGR:1Y: 0.00%2Y: 0.00%5Y: 0.00%10Y: 0.00%

Ratios, Profit Margins & Return on Capital:

AGIO - Net Profit Margin

🔓 See the full chart40% off right now · 7-day free trial

AGIO Net Profit Margin CAGR:1Y: 0.00%2Y: 0.00%5Y: 0.00%10Y: 0.00%

AGIO - Gross Profit Margin

🔓 See the full chart40% off right now · 7-day free trial

AGIO Gross Profit Margin CAGR:1Y: 0.00%2Y: 0.00%5Y: 0.00%10Y: 0.00%

AGIO - Price to Earnings

🔓 See the full chart40% off right now · 7-day free trial

AGIO Price to Earnings CAGR:1Y: 0.00%2Y: 0.00%5Y: 0.00%10Y: 0.00%

AGIO - Price To Sales Ratio

🔓 See the full chart40% off right now · 7-day free trial

AGIO Price To Sales Ratio CAGR:1Y: 0.00%2Y: 0.00%5Y: 0.00%10Y: 0.00%

AGIO - Return on Capital Employed

🔓 See the full chart40% off right now · 7-day free trial

AGIO Return on Capital Employed CAGR:1Y: 0.00%2Y: 0.00%5Y: 0.00%10Y: 0.00%

AGIO - Return on Invested Capital

🔓 See the full chart40% off right now · 7-day free trial

AGIO Return on Invested Capital CAGR:1Y: 0.00%2Y: 0.00%5Y: 0.00%10Y: 0.00%

Projected Future Returns & Dividends for AGIO

Based on past 10-year performance, here are AGIO growth metrics:

Share price CAGR of -4.33%
Dividend CAGR of +0%

Using AGIO CAGR metrics, we can estimate that your initial $10000 investment, over the next 10 years, should grow as follows:

	AGIO (DRIP)	AGIO - No DRIP
Current Price	$33.30	$33.30
Start Shares	300.30	300.30
Start Value	$10,000	$10,000

After 10 years:
Final Share Count	300.30	300.30
Dividends Payment	$0.00	$0.00
Annual Dividends	$0	$0
Yield on cost	0.00%	0.00%
Share Price	$21.40	$33.30
Total Dividends	$0	$0
Final Value	$6,426	$10,000

Estimated Future Value + Dividends - AGIO

NOTE: Above numbers are our estimate based on AGIO's Dividend and Price CAGR over past 10 years. These numbers should only be considered as "potential future returns"! DRIP assumes reinvesting dividends; No-DRIP assumes collecting dividends as cash.

We cannot guarantee that your actual returns will meet these estimates.

Get the best Dividend Stock Research Tools:

Save 25% with annual plan (3 Months Free)

Pro

$171 ($14.25/mo) $102.60/yr ($8.55/mo)

7-day free trial

Unlimited Portfolio Tracker
Portfolio - Lots/Sales/Dividends
Portfolio Auto-DRIP
Stock Fundamentals
DCF valuation modeling
Compare Stocks Side-by-Side
Revenue & EPS Estimates

Try it free for 7 days

You save $125.40 (55%)

Most Popular

Premium

$288 ($24/mo) $172.80/yr ($14.40/mo)

7-day free trial

Everything in Pro
YieldMax PNL Tracker
YieldMax NAV Erosion Alerts
Stocks Dashboard

Try it free for 7 days

You save $211.20 (55%)

Ultra

$576 ($48/mo) $345.60/yr ($28.80/mo)

7-day free trial

Everything in Premium
Group & weekly ETF estimates
YouTuber Mode
Trades summary + CSV export
Priority data & support

Try it free for 7 days

You save $422.40 (55%)

Company Info

Agios Pharmaceuticals, Inc. (AGIO) had its IPO on , and is traded on NASDAQ stock exchange.

Agios Pharmaceuticals, Inc. is a biopharmaceutical company focused on developing medicines for rare diseases through its expertise in cellular metabolism. The company’s core commercial product is PYRUKYND (mitapivat), an oral pyruvate kinase activator used in hemolytic anemia associated with pyruvate kinase deficiency, with additional development in other hematologic and genetically defined disorders. Agios is also advancing investigational therapies for conditions such as thalassemia, sickle cell disease, and phenylketonuria, reflecting its emphasis on rare disease biology and precision medicine. The company operates as a specialized hematology and rare disease developer, combining drug discovery, clinical development, and commercialization capabilities to address unmet medical needs. Agios Pharmaceuticals, Inc. is headquartered in Cambridge, Massachusetts.

AGIO website: https://www.agios.com

Get Full Access to All Reports with DRIPCalc PRO

Save 25% with annual plan (3 Months Free)

Pro

$171 ($14.25/mo) $102.60/yr ($8.55/mo)

7-day free trial

Unlimited Portfolio Tracker
Portfolio - Lots/Sales/Dividends
Portfolio Auto-DRIP
Stock Fundamentals
DCF valuation modeling
Compare Stocks Side-by-Side
Revenue & EPS Estimates

Try it free for 7 days

You save $125.40 (55%)

Most Popular

Premium

$288 ($24/mo) $172.80/yr ($14.40/mo)

7-day free trial

Everything in Pro
YieldMax PNL Tracker
YieldMax NAV Erosion Alerts
Stocks Dashboard

Try it free for 7 days

You save $211.20 (55%)

Ultra

$576 ($48/mo) $345.60/yr ($28.80/mo)

7-day free trial

Everything in Premium
Group & weekly ETF estimates
YouTuber Mode
Trades summary + CSV export
Priority data & support

Try it free for 7 days

You save $422.40 (55%)

Loading signals…

DCF Model — AGIO

Value from:

EPS (TTM)icompany profit per share over the last 12 months

EPS Growth %ihow fast profit per share grows each of the next 5 years — prefilled with what analysts expect

EPS growth after year 5 (forever)ithe slower pace once the fast 5 years are over — only drives years 6-10 of the price path below

Exit multiple (PE in 5 yrs)iwhat buyers pay per $1 of profit in 2031 — prefilled with today’s forward PE

Desired return %/yrithe yearly return you want from buying today — the S&P has done ~14%/yr, ask for more from a single stock

FCF growth %/yr (next 5 yrs)ihow fast free cash flow grows while the company is still expanding fast

Years of fast FCF growthihow many years the fast growth lasts before the business settles down

FCF growth after year 5 (forever)ithe slow, steady pace once the company is mature — usually 2-3%, near inflation. Must stay below your target return

Risk-free rate %iwhat a 10-yr US treasury pays with zero risk — the floor any risky stock must beat

Your target return %/yrithe yearly return you want for taking this risk — rule of thumb: risk-free rate + extra for risk

FCF base ($M, TTM)ilast 12 months of free cash flow, added up from reported quarters

Include dividends in returnidividends hand you part of the return in cash, so the share price needs to climb less

Pay up to today

—

vs current price $33.30

—

Cash flow & implied price by year

FCF is negative or missing for this company (common for banks) — the model discounts EPS instead.

EPS is negative or missing for this company — Simple mode uses free cash flow per share instead.

Free cash flow today

—

grows for the next years

Then mature

—

every future dollar counted back to today

Pile of today-dollars

—

÷ shares

Implied price path

Year	FCF	Implied price

Sensitivity — fair value: growth ↓ × target return →

× Free Portfolio Tracker

Own AGIO? See every dividend it's paid you

Add your AGIO shares to a free account and every payment you've received is listed — dated, in dollars — with reinvested shares counted and monthly totals. Room for 4 more stocks.

✓Every AGIO dividend you've received, dated, with the amount
✓Reinvested (DRIP) shares counted for you
✓Monthly totals across up to 5 stocks

See my AGIO payments →

Free plan · up to 5 holdings